Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders

Spyre Therapeutics is redefining the treatment landscape for inflammatory bowel disease (IBD) by developing long-acting, co-formulated antibody therapies. CEO Cameron Turtle explains that by utilizing YTE modifications to extend drug half-life, the company enables infrequent dosing—potentially quarterly or twice-yearly—while simultaneously addressing the therapeutic ceiling of current treatments. By combining highly specific antibodies against validated targets like alpha-4 beta-7, TL1A, and IL-23, Spyre aims to shift clinical remission rates from the current 25% standard toward 50% or higher. This strategy leverages a platform-based approach to clinical trials, allowing for efficient testing of multiple combinations within a single study. Backed by $1.6 billion in funding, the company focuses on de-risking development through known biology and improved convenience, ultimately seeking to provide durable, high-impact solutions for millions of patients suffering from chronic autoimmune conditions.